Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical trial found that omalizumab (Xolair) was more effective than oral ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy ...

SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with ...

the companies have presented data indicating Xolair may be more effective than oral immunotherapy (OIT) in treating food allergies. Stage 2 of the NIH-sponsored phase 3 OUtMATCH trial—the first ...

The study suggests that omalizumab could become a safer, more effective alternative to OIT for people with highly sensitive ...

Patients with allergies to both peanut and tree nut as ... The researchers also will present results comparing omalizumab with multi-food OIT during the AAAAI/WAO Joint Congress.

Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into a patient’s diet after stopping Xolair. These findings were featured as ...

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions. This renders these ...